Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company. The company focused on developing dermatology pharmaceutical products for a range of UV-related skin disorders. Clinuvel's work aims at preventing the symptoms of diseases related to harmful UV radiation.

Notification of cessation of securities - CUV

Afamelanotide Assists DNA Repair Response Following UVR

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Clinuvel Pharmaceuticals (CUV AU)

Notification of cessation of securities - CUV

Afamelanotide Assists DNA Repair Response Following UVR

CLINUVEL extends Managing Director Employment Agreement

SCENESSE European Orphan Drug Designation for VP

afamelanotide in fair-skinned Parkinsons patients

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)